Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation

Bone Marrow Transplantation

Volumn 37, Issue 2, 2006, Pages 155-163

  Dahlke, J ^a   Kroger N ^a   Zabelina, T ^a   Ayuk, F ^a   Fehse, N ^a   Wolschke, C ^a   Waschke, O ^a   Schieder, H ^a   Renges, H ^a   Kruger W ^a   Kruell, A ^a   Hinke, A ^b   Erttmann, R ^a   Kabisch, H ^a   Zander, A R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Wissenschaftlicher Service Pharma   (Germany)

Author keywords

Acute lymphoblastic leukemia; Allogeneic; Unrelated

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; METHOTREXATE; OFLOXACIN; PENTAMIDINE; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DONOR SELECTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HERPES; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER DISEASE; LIVER DYSFUNCTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; MYCOSIS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SERODIAGNOSIS; SEX DIFFERENCE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; DISEASE-FREE SURVIVAL; DONOR SELECTION; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 30944466125     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705221     Document Type: Article

References (48)

1. Bunin N, Carston M, Wall D, Adams R, Casper J, Naynesh K et al. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 2002; 99: 3151-3157.
2. Forman SJ. The role of allogeneic bone marrow transplantation in the treatment of high-risk acute lymphocytic leukaemia in adults. Leukemia 1997; 11: 18-19.
3. Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S et al. Factors affecting the outcome of Allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 1999; 107: 409-419.
4. Thiebaut A, Vernant JP, Degos L, Huguet FR, Reiffers J, Sebban C et al. Adult acute lymphocytic leukaemia study testing chemotherapy and autologous and allogeneic transplantation: A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000; 14: 1353-1366.
5. Biggs JC, Horowitz MM, Gale RP, Ash RC, Atkinson K, Helbig W et al. Bone marrow transplants may cure patients with acute leukaemia never achieving remission with chemotherapy. Blood 1992; 80: 1090-1093.
6. Schiller G, Feig SA, Territo M, Wolin M, Lill M, Belin T et al. Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol 1994; 88: 72-78.
7. Al-Kasim FA, Thornley I, Rolland M, Lau W, Tsang R, Freedman MH et al. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukemia in childhood: Similar survival after matched-related and matched-unrelated donor transplant. Br J Haematol 2002; 116: 483-490.
8. Cornelissen JJ, Carston M, Kollman C, King R, Dekker AW, Lowenberg B et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572-1577.
9. Kroger N, Kruger W, Wacker-Backhaus G, Hegewisch-Becker S, Stockschlader M, Fuchs N et al. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 22: 1029-1033.
10. Saarinen-Pihkala UM, Gustafsson G, Ringden O, Heilmann C, Glomstein A, Lonnerholm G et al. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukaemia in second remission. J Clin Oncol 2001; 19: 3406-3414.
11. Hows JM. Paediatric bone marrow transplantation using donors other than HLA genotypically identical siblings. Arch Dis Child 1991; 66: 546-550.
12. O'Reilly J. Bone marrow transplants in patients lacking an HLA-matched sibling donor. Pediatr Ann 1991; 20: 682-690.
13. Nademanee A, Schmidt GM, Parker P, Dagis AC, Stein A, Snyder DS et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate and prednisone. Blood 1995; 86: 1228-1234.
14. Petersdorf EW, Longton GM, Anasetti C, Martin PJ, Mickelson EM, Smith AG et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606-1613.
15. Small TN, Avigan D, Dupont B, Smith K, Black P, Heller G et al. Immune reconstitution following T-cell depleted bone marrow transplantation: Effect of age and post-transplant graft rejection prophylaxis. Biol Blood Marrow Transplant 1997; 3: 65.
16. Small TN, Papadopoulos EB, Boulad F, Black P, Castro-Malaspina H, Childs BH et al. Comparison of immune reconstitution after unrelated T-cell depleted bone marrow transplantation: Effect of patient age and donor leukocyte engraftment infusions. Blood 1999; 93: 467-480.
17. Speiser DE, Tiercy J-M, Rufer N, Grundschobet C, Gratwohl A, Chapuis B et al. High resolution HLA matching associated with decreased mortalityafter unrelated bone marrow transplantation. Blood 1996; 87: 4455.
18. Kroger N, Zabelina T, Kruger W, Renges H, Stute N, Durken M et al. Anti-Thymocyte-globulin as a part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Hematol 2001; 80: 209-215.
19. Zander AR, Kroger N, Schleuning M, Finke J, Zabelina T, Beelen D et al. ATG as a part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 2003; 32: 355-361.
20. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Internal Med 1993; 118: 173-178.
21. Kroger N, Zabelin T, Kruger W, Renges H, Stute N, Schrum J et al. Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 2001; 113: 1060-1071.
22. Marras TK, Sanders K, Lipton JH, Messner HA, Conly J, Chan CK. Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transplant Infect Dis 2002; 4: 66-74.
23. Mehta J, Powles R, Singhal S, Riley U, Treleaven J, Catovsky D. Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukaemia after allogeneic blood or marrow transplantation. Leuk Lymphoma 1997; 26: 83-88.
24. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
25. Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N et al. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia - no difference in related compared to unrelated transplant. J Clin Oncol 2004; 22: 2816-2825.
26. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Lerner KG et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
27. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
28. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
29. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venoocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
30. Kaplan E, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
31. Cox D. Regression models and life tables. J R Stat Soc 1972; 34: 187-202.
32. McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R et al. Unrelated donor marrow transplantation for chronic myelogenous leukaemia: 9 years experience of the National Marrow Donor Program. Blood 2000; 95: 2219-2225.
33. Doney K, Fisher LD, Appelbaum FR, Buckner CD, Storb R, Singer J et al. Treatment of adult acute lymphoblastic leukaemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 1991; 7: 453-459.
34. Tabata M, Satake A, Okura N, Yamazaki Y, Toda A, Nishioka K et al. Long-term outcome after allogeneic bone marrow transplantation for hematological malignancies with non-remission status-Results of a single-center study of 24 patients. Ann Hematol 2002; 81: 582-587.
35. Gorin NC, Labopin M, Polge E, Cordonnier C, Jouet JP, Michallet M et al. Risk assessment in adult lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: An easy clinical score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation. Leukemia 2003; 17: 1596-1599.
36. Passweg JR, Tiberghien P, Cahn JY, Vowels MR, Camitta BM, Gale RP et al. Graft-versus-Leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 21: 153-158.
37. Arnold R, Massenkeil G, Bornhauser M, Ehninger G, Beelen DW, Fauser AA et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not advanced disease. Leukemia 2002; 16: 2423-2428.
38. Spencer A, Szydlo RM, Brookes PA, Kaminski E, Rule S, van Rhee F et al. Bone marrow transplantation for chronic myeloid leukaemia with volunteer unrelated donors using ex vivo T-cell depletion: Major prognostic impact of HLA class I identity between donor and recipient. Blood 1995; 86: 3590-3597.
39. Bacigalupo A, Tedone E, Isaza A, Van Lint MT, Moro F, Trespi G et al. CMV antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell number with transplant-related mortality. Bone Marrow Transplant 1995; 16: 155-161.
40. Broers AE, van der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V et al. Increased transplant-related morbidity and mortality in CMV seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell depleted stem cell transplantation. Blood 2000; 95: 2240-2245.
41. Couriel D, Canosa J, Engler H, Collins A, Dunbar C, Barrett AJ. Early reactivation of cytomegalovirus and high risk of interstitial pneumonia following T-cell depleted BMT for adults with haematological malignancies. Bone Marrow Transplant 1996; 18: 347-351.
42. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand? Blood 1994; 83: 2392-2398.
43. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infection Disease 1986; 153: 478-488.
44. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087-1092.
45. Carlens S, Ringden O, Remberger M, Lonnqvist B, Hagglu H, Klaesson S et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: A retrospective single centre analysis. Bone Marrow Transplant 1998; 22: 755-761.
46. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C et al. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1972-1974.
47. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51: 1197-1203.
48. Ringden O, Labopin M, Tura S, Arcese W, Iriondo A, Zittoun R et al. A comparison of busulfan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia: Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996; 93: 637-645.